ChemicalBook > Product Catalog >API >Hormones and the Endocrine System >Pancreatic hormone and blood sugar regulation >Voglibose

Voglibose

Voglibose Suppliers list
Company Name: Shanghai finete Pharmaceutical Co., Ltd.
Tel: +86-18221039705
Email: sales@finetechpharm.com
Products Intro: Product Name:Voglibose
CAS:83480-29-9
Purity:99% HPLC Package:1g; 10g; 100g ;500g;1000g;
Company Name: Jinan Jianfeng Chemical Co., Ltd
Tel: 15562555968
Email: info@pharmachemm.com
Products Intro: Product Name:Voglibose
CAS:83480-29-9
Purity:99% Package:5KG;1KG;25kg Remarks:pharm intermediate
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Voglibose
CAS:83480-29-9
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Voglibose
CAS:83480-29-9
Purity:99% Package:100g,500g,1kg,5kg,10kg
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:Voglibose
CAS:83480-29-9
Purity:98% Package:100G;1KG;50KG;100KG;1000KG

Lastest Price from Voglibose manufacturers

  • Voglibose
  • US $1.00 / g
  • 2019-07-31
  • CAS:83480-29-9
  • Min. Order: 1g
  • Purity: 99.5%
  • Supply Ability: 1000 Kilogram/Kilograms per Month
  • Voglibose
  • US $200.00 / KG
  • 2019-07-06
  • CAS:83480-29-9
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 100kg
  • Voglibose
  • US $100.00 / KG
  • 2019-07-06
  • CAS:83480-29-9
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: Customized

Related articles

Voglibose Basic information
Oral hypoglycemic agents Side Effects Uses
Product Name:Voglibose
Synonyms:Voglistat;epi-Inositol, 2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-C-(hydroxymethyl)-;2,3-Dideoxy-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-4-C-(hydroxymethyl)-epi-inositol;Beigrace;Jumeal;Voglibose ,98%;3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol;N-(1,3-Dihydroxyprop-2-yl)valiolamine
CAS:83480-29-9
MF:C10H21NO7
MW:267.28
EINECS:1312995-182-4
Product Categories:Diabetes Research;Carbohydrates & Derivatives;Miscellaneous;VOGLIBOSE;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:83480-29-9.mol
Voglibose Structure
Voglibose Chemical Properties
Melting point 162-163°C
alpha D25 +26.2° (c = 1 in water)
Boiling point 601.9±55.0 °C(Predicted)
density 1.58±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
pka13.26±0.70(Predicted)
Merck 14,10029
InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-N
CAS DataBase Reference83480-29-9(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 20/21/22-36/37/38
Safety Statements 36/37-37/39-26
WGK Germany 3
RTECS NM7524600
Voglibose Usage And Synthesis
Oral hypoglycemic agentsVoglibose is an oral hypoglycemic agents which can alleviate the postprandial hyperglycemia of diabetes patients. It is first successfully developed by the Takeda Company in Japan. It belongs to α-glucosidase inhibitor (a drug which can delay the intestinal absorption of carbohydrates to achieve hypoglycemic effect). Its mechanism of action is through inhibiting the activity of disaccharides hydrolase (α-glucosidase) which can hydrolyze disaccharide into monosaccharide inside the gut and thus delaying the digestion and absorption of sugar and further alleviating the postprandial hyperglycemia. In the assay of measuring the exhaled hydrogen of healthy adults given sucrose loading, the results have confirmed that this drug in its clinical dosage has an inhibitory effect on hyperglycemia. When normal rats are subject to oral administration, this product can inhibit the increased blood sugar level after the increased loading of starch, sucrose, glucose and maltose, while it has no inhibitory effect on the increased blood sugar after increased loading of glucose, fructose, and lactose. In vitro analysis of mechanism of action have shown that, for the maltase and sucrose obtained from the small intestine of pig and rat, this drug has a strong inhibitory effect; on the other hand, it has a relative low inhibitory effect on the pancreatic α-amylase of pig and rat and has no inhibitory effect on β-glucosidase. It has a competitive inhibitory effect on the disaccharide hydrolase of the isomaltase-sucrase complex from the rat small intestine.
It is understood that voglibose has a broad scope of application; it is not only suitable for elderly patients with diabetes, but also has significant efficacy on patients with refractory type II diabetes, patients with secondary failure of sulfonylureas, patients with combined hyperlipidemia diabetes, patients with merged cardiovascular diabetes disease as well as patients with combined hyperinsulinemia. Because this product does not stimulate the secretion of insulin, it can reduce the harmful effects of postprandial hyperinsulinemia, reducing the resistance of insulin and contributes to the prevention and treatment of metabolic syndrome such as cardiovascular complications.
Side EffectsMechanism of occurrence of side effects of oral administration of hypoglycemic agents is generally that: when the unabsorbed carbohydrate enters into the large intestine, under the action of bacteria, it subjects to glycolysis which produces carbon dioxide, hydrogen, and organic acids. At the same time, because of the increased osmotic pressure of intestinal, water retention happen which therefore causes increased exhausting, bloating, and diarrhea. Since voglibose can selectively inhibit the activity of the disaccharide hydrolase in the intestine, further delaying the rapid digestion and absorption of carbohydrate in the upper small intestine, and thus reducing saccharide, leading to a lower incidence of adverse reactions. It is known to have the following adverse reactions:
1. The digestive system: diarrhea, loose stools, borborygumus, abdominal pain, constipation, loss of appetite, nausea, vomiting, heartburn (incidence of 0.1 to 5%), stomatitis, thirst, abnormal taste, and pneumatosis cystoides gastrointestinalis (0.1%).
2. Allergic symptoms: rash, itching, light sensitivity (incidence of 0.1% or less).
3. Liver: GOT, GPT, LDH, γ-GTP, ALP are increased (0.1% incidence).
4. The nervous system: headache, dizziness, staggering, drowsiness (0.1% incidence).
5. The blood system: anemia (incidence of 0.1 to 5%), thrombocytopenia (0.1%).
6. Other: paralysis, facial swelling, hazy eyes, fever, flu, tiredness, feeling of fatigue, hyperkalemia, rise of serum amylase, decrease of high-density lipoprotein, sweating, hair loss (incidence of 0.1%).
The above information is edited by the chemicalbook of Dai Xiongfeng.
Uses1. It is used for treating diabetes.
2. Anti-diabetic drug.
DescriptionVoglibose was introduced in Japan for the treatment of postprandial hyperglycemia in diabetic patients. As an orally active α-D-glucosidase inhibitor, it is effective in decreasing the release of glucose from carbohydrate ingestion and slowing the increase of postprandial blood glucose levels, as demonstrated in animals and humans following sucrose and starch loading. In addlion, voglibose was reported to have prophylactic effect in genetically obese Wistar rats, maintaining low plasma levels of glucose, triglyceride and insulin, indicating a potential usefulness for the management of other carbohydrate-dependent metabolic disorders such as obesity. Voglibose is much more potent and has fewer side effects than acarbose, another agent in its class.
Chemical PropertiesColourless Crystalline Solid
OriginatorTakeda (Japan)
UsesAn α-Glucosidase inhibitor used as an antidiabetic.
UsesFor the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
UsesAn alpha-Glucosidase inhibitor used as an antidiabetic
Manufacturing ProcessN-(1,3-Dihydroxy-2-propyl)valiolamine:
To a solution of 2.0 g of valiol amine in 50 ml of N,N-dimethylformamide are added 3.4 g of dihydroxyacetone, 1.5 ml of 2 N hydrochloric acid and 2.6 g of sodium cyanoborohydride, followed by stirring at 60 to 70°C for 16 hours. The reaction solution is concentrated under reduced pressure to distill off the N,N- dimethylformamide as much as possible, and the residue is dissolved in 100 ml of water. The solution is made acid with 2 N hydrochloric acid, stirred for 30 to 40 minutes under ice-cooling, adjusted to pH 4.5 with 1 N sodium hydroxide solution and subjected to column chromatography (250 ml) on Dowex 50W x 8 (H + type) (produced by Dow Chemical of the United States of America). After the washing with water, the elution is carried out with 0.5 N aqueous ammonia. The eluate is concentrated under reduced pressure, and the concentrate is chromatographed on a column (250 ml) of Amberlite CG-50 (NH 4 + type) (produced by Rohm and Haas Co. of the United States of America), followed by the elution with water. The eluate is concentrated under reduced pressure, and the concentrate is lyophilized to give 2.0 g of white powder of N-(1,3-dihydroxy-2-propyl)valiol amine.
Ethanol (about 60 ml) is added to the above lyophilized product (1.2 g) of N- (1,3-dihydroxy-2-propyl)valiol amine, and the mixture is warmed for 30 minutes in a hot water bath (the bath temperature: 90-95°C), followed by leaving on standing in a refiegerator. The resultant crystalline substance is recovered by filtration, washed with ethanol and then dried in a desiccator under reduced pressure. Yield of 0.95 g. MP: 162-163°C. [α] D 25 = +26.2° (c = 1, H 2 O).
Brand nameBasen (Takeda); Glustat (Takeda).
Therapeutic FunctionAntidiabetic, Antiobesity
World Health Organization (WHO)Acarbose and voglibose area-glucosidase inhibitors and delay digestion/absorption of carbohydrates as well as improving postprandial hyperglycaemia.
Biological ActivityOrally active α -glucosidase inhibitor (IC 50 values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo .
Voglibose Preparation Products And Raw materials
Raw materialsSodium cyanoborohydride-->DOWEX 50WX4-200R ION-EXCHANGE RESIN-->1,3-Dihydroxyacetone-->Valiolamine-->AMBERLITE
Tag:Voglibose(83480-29-9) Related Product Information
Acarbose Miglitol Pioglitazone hydrochloride EPI-INOSITOL Voglibose(Volix) Voglibose,HypoglycemicAgent 2,3,4,6-TETRA-O-BENZYL-D-GLUCOPYRANOSE VOGLIBOSE PROPANEDIOLAMINE(BENZOYL PROTECTED) TETRABENZYL-VOGLIBOSE Voglibose Cyclohexanone Acetaminophen Tris Base Molasses Trimethylolpropane Cyclohexane Glibornuride